Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma. Primary Objective * To assess if the flow-cytometry assessed MRD-negative remission rate following an immunotherapy-based Induction in NCI-high risk patients without favorable genetic features is higher than the results of similar patients treated on AALL1131. Secondary Objectives * To compare flow-cytometry assessed MRD-negative rates at t

Trial Details

NCT ID
NCT06533748
Phase
PHASE2
Sponsor
St. Jude Children's Research Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Dexamethasone
  • Vincristine
  • Inotuzumab
  • Blinatumomab
  • Dasatinib
  • IT MHA
Locations (sample)
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Tulsa, Oklahoma, United States|36.15398,-95.99277
  • Memphis, Tennessee, United States|35.14953,-90.04898

Key Eligibility Criteria

  • Enrollment on INITIALL.
  • Age 1-18.99 years at the time of enrollment on INITIALL.
  • B-Acute lymphoblastic leukemia or lymphoblastic lymphoma.
  • No prior chemotherapy excluding therapy given on or allowed by INITIALL.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →